Keystone Symposia

This meeting took place in 2016

Here are the related meetings in 2021:
MEETING CHANGE TO VIRTUAL: Harnessing the Microbiome for Disease Prevention and Therapy (J4)
Harnessing the Microbiome for Disease Prevention and Therapy (EK12)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Gut Microbiota, Metabolic Disorders and Beyond (D4)

Organizer(s) Rémy G. Burcelin, Sven Pettersson and Tak W. Mak
April 17—21, 2016
Hyatt Regency Newport • Newport, RI USA
Discounted Abstract Deadline: Dec 17, 2015
Abstract Deadline: Jan 20, 2016
Scholarship Deadline: Dec 17, 2015
Discounted Registration Deadline: Feb 17, 2016

Sponsored by Curemark LLC, Nestlé Institute of Health Sciences and Novartis Institutes for BioMedical Research

Summary of Meeting:
The hologenome theory of evolution proposes that natural selection acts not on the individual organism but rather on the “holobiont,” which consists of the organism together with microbiome (its genes and metabolites). When a holobiont is challenged by dramatic changes, such as altered diet or reduced physical activity, it employs adaptive mechanisms in the form of reshuffling its microbiome (resident microbial communities), but the underlying mechanisms of this molecular crosstalk remain to be determined. Effective study of the holobiont requires a systems biology approach: remove one component of the holobiont to study it in reductionist style and other parts also altered will be overlooked. Decades of reductionist research aimed at understanding the mechanisms responsible for the current dramatic epidemic of man-made metabolic diseases have not considered the holobiont perspective and have consequently missed the adaptation strategies of the microbiome but have set the stage to explore the inchoate holobiont perspective. Application of a systems biology approach to decipher molecular mechanisms underlying man-made metabolic diseases presents a unique opportunity to develop novel therapies that sustain health in a personalized manner. This meeting will discuss how the gut microbiome and its metabolites influence major molecular and physiological mechanisms responsible for man-made metabolic diseases. It will therefore incorporate investigators from diverse areas such as medicine, immunology, neurobiology, endocrinology, physiology, psychiatry, systems biology and microbiology. In addition, the nutritional, surgical and pharmacological aspects of innovative therapeutic strategies will be discussed in dialogue with scientists from pharmaceutical/nutritional companies. The gut microbiome is a neuroendocrine and antigenic organ whose rediscovery is necessary for our understanding of man-made metabolic diseases in the context of the holobiont.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Maayan Levy
University of Pennsylvania, USA

Rebecca M. Pollet
University of North Carolina at Chapel Hill, USA

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Scholarship Recipients

Joseph F. Cavallari
McMaster University, Canada

Youngji (Helen) Cho
Harvard University, USA

Pieter F. de Groot
Academic Medical Centre, Netherlands

Carmen A.K. Emborski
Texas Tech University, USA

Ara Koh
Gothenburg University, Sweden

Shirong Liu
Brigham and Women's Hospital/Harvard Medical School, USA

The Elkes Foundation Scholarship Recipients

Rebecca Schugar
Cleveland Clinic Lerner Research Institute, USA

Taylor Kristina Soderborg
University of Colorado Denver, USA